BioLineRx Ltd.
BLRX
$3.28
-$0.06-1.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 40.46% | 19.22% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 40.46% | 19.22% | |||
| Cost of Revenue | 16.67% | 111.76% | |||
| Gross Profit | 47.84% | 4.98% | |||
| SG&A Expenses | 297.61% | -78.87% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 1.04% | -1.47% | |||
| Operating Income | 4.17% | 3.68% | |||
| Income Before Tax | 75.20% | -176.85% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 75.20% | -176.85% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 75.20% | -176.85% | |||
| EBIT | 4.17% | 3.68% | |||
| EBITDA | 1.83% | 4.45% | |||
| EPS Basic | 76.47% | -173.91% | |||
| Normalized Basic EPS | 80.00% | -171.43% | |||
| EPS Diluted | 76.47% | -173.91% | |||
| Normalized Diluted EPS | 80.00% | -171.43% | |||
| Average Basic Shares Outstanding | 10.02% | 6.85% | |||
| Average Diluted Shares Outstanding | 10.02% | 6.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||